These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22990720)

  • 21. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered functional connectivity in blepharospasm/orofacial dystonia.
    Jochim A; Li Y; Gora-Stahlberg G; Mantel T; Berndt M; Castrop F; Dresel C; Haslinger B
    Brain Behav; 2018 Jan; 8(1):e00894. PubMed ID: 29568690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitochondriopathy, blepharospasm, and treatment with botulinum toxin.
    Müller-Vahl KR; Kolbe H; Egensperger R; Dengler R
    Muscle Nerve; 2000 Apr; 23(4):647-8. PubMed ID: 10716779
    [No Abstract]   [Full Text] [Related]  

  • 24. Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore.
    Tan AK
    Singapore Med J; 1998 Sep; 39(9):403-5. PubMed ID: 9885719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Self-reported benefit and weakness after botulinum toxin in dystonia.
    Kassavetis P; Lungu C; Ehrlich D; Alter K; Karp BI
    Parkinsonism Relat Disord; 2020 Nov; 80():10-11. PubMed ID: 32927341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm.
    Jankovic J
    Eur J Neurol; 2009 Dec; 16 Suppl 2():14-8. PubMed ID: 20002742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A survey about the accessibility to botulinum toxin therapy for dystonia].
    Mezaki T; Hayashi A; Nakase H; Hasegawa K
    No To Shinkei; 2006 Mar; 58(3):219-24. PubMed ID: 16629446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Botulinum toxin in the treatment of facial dystonia: evaluation of its efficacy and patients' satisfaction along the treatment].
    Costa PG; Aoki L; Saraiva FP; Matayoshi S
    Arq Bras Oftalmol; 2005; 68(4):471-4. PubMed ID: 16322831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum toxin: from toxin to therapeutic agent.
    Behari M; Goyal V
    J Assoc Physicians India; 2000 Feb; 48(2):225-33. PubMed ID: 11229154
    [No Abstract]   [Full Text] [Related]  

  • 30. [Botulinum toxin in the treatment of focal dystonias: own experience with botulinum toxin].
    Stefanoff P; Kiliszek M; Friedman A
    Neurol Neurochir Pol; 2000; 34(1):61-70. PubMed ID: 10849905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of primary blepharospasm in Sardinia, Italy: a service-based survey.
    Cossu G; Mereu A; Deriu M; Melis M; Molari A; Melis G; Minafra L; Pisano T; Cianchetti C; Ortu E; Sau G; Aiello I; Fresu M; Marrosu MG; Contu P
    Mov Disord; 2006 Nov; 21(11):2005-8. PubMed ID: 16960861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dystonia: medical therapy and botulinum toxin.
    Jankovic J
    Adv Neurol; 2004; 94():275-86. PubMed ID: 14509685
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of botulinum toxin A in the treatment of hemifacial spasm and blepharospasm.
    Chang LB; Tsai CP; Liao KK; Kao KP; Yuan CL; Yen DJ; Lin KP
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jan; 62(1):1-5. PubMed ID: 10063705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frontalis suspension in the treatment of essential blepharospasm unresponsive to botulinum-toxin therapy: long-term results.
    Roggenkämper P; Nüssgens Z
    Graefes Arch Clin Exp Ophthalmol; 1997 Aug; 235(8):486-9. PubMed ID: 9285216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin in the treatment of neurological disorders.
    Denislic M; Pirtosek Z; Vodusek DB; Zidar J; Meh D
    Ann N Y Acad Sci; 1994 Mar; 710():76-87. PubMed ID: 8154763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study.
    Mezaki T; Kaji R; Kohara N; Fujii H; Katayama M; Shimizu T; Kimura J; Brin MF
    Neurology; 1995 Mar; 45(3 Pt 1):506-8. PubMed ID: 7898706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Botulinum toxin therapy for focal dystonia].
    Hahn K; Niklai E; Garzuly F; Szupera Z
    Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Botulinum toxin for the treatment of movement disorders.
    Thenganatt MA; Fahn S
    Curr Neurol Neurosci Rep; 2012 Aug; 12(4):399-409. PubMed ID: 22661378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Focal or Segmental Dystonia Resistant to Botulinum Toxin: How Do You Treat Patients in Whom Botulinum Toxin Treatment Has No Effect?].
    Nomura T
    Brain Nerve; 2022 May; 74(5):581-587. PubMed ID: 35589651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Use of botulinum toxin in ophthalmology: current concepts and problems].
    Tapiero B; Robert PY; Adenis JP; Riss I
    J Fr Ophtalmol; 1997; 20(2):134-45. PubMed ID: 9099272
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.